Cancer vaccine-GVAX: potential in NSCLC

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1434, 2004-01, pp. : 10-10

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The GVAX cancer vaccine plus ipilimumab is active in the treatment of patients with advanced prostate cancer

By  

Inpharma, Vol. 1, Iss. 1577, 2007-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

Cancer vaccine-GVAX/leuprorelin/nadroparin calcium: Delayed-type hypersensitivity in an elderly patient: case report

By  

Reactions Weekly, Vol. 1, Iss. 1254, 2009-01 ,pp. : 13-13

Adis International

Access to resources Recommend Favorite

A semiallogeneic cancer vaccine has potential in the treatment of cancer

By  

Inpharma, Vol. 1, Iss. 1276, 2001-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

L-BLP25 vaccine extends survival in NSCLC

By  

Inpharma, Vol. 1, Iss. 1470, 2005-01 ,pp. : 7-8

Adis International

Access to resources Recommend Favorite

Important Times for Cancer Vaccine

By Wright T.  

Pharmaceutical & Diagnostic Innovation, Vol. 2, Iss. 2, 2004-06 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite